BioNTech SE (BNTX) shareholders
Close on Nov 13, 2026Market cap $21.50BP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| AT Impf GmbH Joint filing with Athos Kg (40.20%), Thomas Maier (40.20%) | 101,702,378 | 40.20% | 13G (passive) amendment | Mar 31, 2026 |
| Prof. Ugur Sahin, M.D. Joint filing with Medine GmbH (16.70%) | 42,178,034 | 17.60% | 13G (passive) amendment | Mar 31, 2025 |
| Ugur Sahin Joint filing with Medine GmbH (15.50%) | 40,076,320 | 15.80% | 13G (passive) amendment | Mar 31, 2026 |
| BioNTech SE | 33,333,333 | – | 13D (active) | Feb 13, 2024 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of BNTX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| FMR LLC | 7,571,805 | 3.01% | $704.56M | +1,862,565 | 0.03% |
| Primecap Management Co/Ca/ | 3,772,031 | 1.50% | $350.99M | −21,680 | 0.21% |
| Dodge & Cox | 3,677,591 | 1.46% | $342.20M | +800 | 0.18% |
| Flossbach Von Storch AG | 2,226,138 | 0.89% | $207.14M | −1,454,177 | 0.94% |
| T. Rowe Price Investment Management, Inc. | 2,065,456 | 0.82% | $192.19M | −3,790,617 | 0.13% |
| BlackRock, Inc. | 1,854,966 | 0.74% | $172.60M | +196,813 | 0.00% |
| Temasek Holdings (Private) Ltd | 1,506,027 | 0.60% | $140.14M | – | 0.38% |
| Bnp Paribas Arbitrage, Snc | 1,319,517 | 0.53% | $122.78M | −332,272 | 0.04% |
| Logos Global Management LP | 1,015,000 | 0.40% | $94.45M | New | 4.07% |
| GSK plc | 889,824 | 0.35% | $82.80M | – | 13.75% |
| Assenagon Asset Management S.A. | 846,526 | 0.34% | $78.77M | New | 0.05% |
| First Trust Advisors LP | 791,469 | 0.32% | $73.65M | −48,522 | 0.04% |
| Davern Capital Partners, LP | 754,550 | 0.30% | $70.21M | +449,495 | 11.97% |
| UBS Asset Management Americas Inc | 744,200 | 0.30% | $69.25M | −39,795 | 0.01% |
| Massachusetts Financial Services Co /Ma/ | 677,708 | 0.27% | $63.06M | +7,194 | 0.02% |
| Long Focus Capital Management, LLC | 624,000 | 0.25% | $58.06M | – | 1.48% |
| Baillie Gifford & Co | 592,380 | 0.24% | $55.12M | −290,192 | 0.05% |
| Goldman Sachs Group Inc | 589,903 | 0.23% | $54.89M | +493,074 | 0.00% |
| Victory Capital Management Inc | 539,787 | 0.21% | $50.23M | +62,864 | 0.03% |
| Franklin Resources Inc | 539,593 | 0.21% | $50.21M | +154,967 | 0.01% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 282 | 47M | 18.9% | 43 / 93 | 71 / 30 | 8M | 8M |
| Q1 2026 | 272 | 48M | 18.9% | 41 / 90 | 76 / 51 | 5M | 8M |
| Q4 2025 | 284 | 51M | 20.3% | 67 / 85 | 75 / 35 | 12M | 11M |
| Q3 2025 | 254 | 51M | 20.1% | 34 / 70 | 88 / 36 | 7M | 10M |
| Q2 2025 | 258 | 54M | 21.4% | 33 / 85 | 82 / 51 | 8M | 6M |
| Q1 2025 | 279 | 52M | 20.6% | 39 / 76 | 100 / 58 | 5M | 4M |
| Q4 2024 | 303 | 51M | 20.2% | 63 / 84 | 88 / 49 | 11M | 4M |
| Q3 2024 | 297 | 44M | 17.6% | 77 / 73 | 96 / 64 | 14M | 8M |
| Q2 2024 | 286 | 41M | 16.4% | 37 / 87 | 99 / 36 | 6M | 8M |
| Q1 2024 | 287 | 43M | 17.2% | 50 / 97 | 88 / 43 | 6M | 4M |
| Q4 2023 | 282 | 41M | 16.5% | 70 / 92 | 70 / 38 | 7M | 3M |
| Q3 2023 | 252 | 37M | 14.7% | 33 / 72 | 76 / 31 | 4M | 4M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
124 funds held BNTX in Q2 2026, 13% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of BNTX | Value | % of fund | As of |
|---|---|---|---|---|---|
| Fidelity Contrafund | 3,278,252 | 1.31% | $305.04M | 0.17% | Jun 30, 2026 |
| Dodge & Cox International Stock Fund | 2,517,713 | 1.00% | $234.27M | 0.35% | Jun 30, 2026 |
| Vanguard Capital Opportunity Fund | 2,189,120 | 0.87% | $203.70M | 0.62% | Jun 30, 2026 |
| T. Rowe Price Mid-Cap Growth Fund, Inc. | 1,018,613 | 0.41% | $94.78M | 0.41% | Jun 30, 2026 |
| PRIMECAP Odyssey Aggressive Growth Fund | 897,156 | 0.36% | $81.26M | 1.10% | Jul 31, 2026 |
| First Trust NYSE Arca Biotechnology Index Fund | 794,727 | 0.32% | $73.95M | 2.63% | Jun 30, 2026 |
| Fidelity Contrafund K6 | 704,487 | 0.28% | $65.55M | 0.17% | Jun 30, 2026 |
| Fidelity Emerging Markets Fund | 660,800 | 0.26% | $59.86M | 0.55% | Jul 31, 2026 |
| iShares Biotechnology ETF | 647,133 | 0.26% | $60.22M | 0.66% | Jun 30, 2026 |
| Dodge & Cox Global Stock Fund | 525,778 | 0.21% | $48.92M | 0.38% | Jun 30, 2026 |
| MFS Mid Cap Value Fund | 487,157 | 0.19% | $45.33M | 0.26% | Jun 30, 2026 |
| PRIMECAP Odyssey Growth Fund | 354,600 | 0.14% | $32.12M | 0.53% | Jul 31, 2026 |
| Strategic Advisers Fidelity Emerging Markets Fund | 244,800 | 0.10% | $23.49M | 0.06% | May 31, 2026 |
| Fidelity Value Fund | 200,000 | 0.08% | $18.12M | 0.17% | Jul 31, 2026 |
| Schwab Fundamental International Equity ETF | 196,561 | 0.08% | $18.86M | 0.08% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Ugur Sahin | Chief Executive Officer, 10% owner | 39,218,111 | 15.61% | Oct 9, 2026 |
| Annemarie Hanekamp | Chief Commercial Officer | – | – | May 13, 2026 |
| James Timothy Patrick Ryan | See remarks. | 4,795 | 0.00% | May 13, 2026 |
| Kylie Jimenez | Chief People Officer | – | – | May 13, 2026 |
| Gomez Ramon Zapata | Chief Financial Officer | – | – | May 13, 2026 |
| Sierk Poetting | Chief Operating Officer | 540,901 | 0.22% | May 13, 2026 |
| Ozlem Tureci | Chief Medical Officer | – | – | Mar 18, 2026 |
| Iris Katharina Low-Friedrich | Director | – | – | Jun 26, 2026 |
| Susanne Schaffert | Director | – | – | Jun 26, 2026 |
| Nicola Claire Blackwood | Director | – | – | Mar 25, 2026 |
| Anja Morawietz | Director | 240 | 0.00% | Mar 25, 2026 |
| Rudolf Staudigl | Director | 400 | 0.00% | Mar 25, 2026 |
| Helmut Wolfgang Jeggle | Director | 989,267 | 0.39% | Mar 18, 2026 |
| Michael Motschmann | Director | – | – | Mar 18, 2026 |
| Ulrich Wandschneider | Director | 1,927 | 0.00% | Mar 18, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Ugur Sahin Chief Executive Officer, 10% owner | Oct 9, 2026 | Sale(10b5-1 plan) | −36,209 | $95.37 | $3.45M | 0 |
| Ugur Sahin Chief Executive Officer, 10% owner | Oct 8, 2026 | Sale(10b5-1 plan) | −27,000 | $92.31 | $2.49M | 36,209 |
| Ugur Sahin Chief Executive Officer, 10% owner | Oct 7, 2026 | Sale(10b5-1 plan) | −24,000 | $95.86 | $2.30M | 63,209 |
| Ugur Sahin Chief Executive Officer, 10% owner | Oct 6, 2026 | Sale(10b5-1 plan) | −21,000 | $96.81 | $2.03M | 87,209 |
| Ugur Sahin Chief Executive Officer, 10% owner | Oct 5, 2026 | Sale(10b5-1 plan) | −72,000 | $97.23 | $7.00M | 108,209 |
| Ugur Sahin Chief Executive Officer, 10% owner | Oct 2, 2026 | Sale(10b5-1 plan) | −17,000 | $96.72 | $1.64M | 180,209 |
| Ugur Sahin Chief Executive Officer, 10% owner | Oct 1, 2026 | Sale(10b5-1 plan) | −17,000 | $97.46 | $1.66M | 197,209 |
| Ugur Sahin Chief Executive Officer, 10% owner | Sep 30, 2026 | Sale(10b5-1 plan) | −32,000 | $98.12 | $3.14M | 214,209 |
| Ugur Sahin Chief Executive Officer, 10% owner | Sep 29, 2026 | Sale(10b5-1 plan) | −34,000 | $98.26 | $3.34M | 246,209 |
| Ugur Sahin Chief Executive Officer, 10% owner | Sep 28, 2026 | Sale(10b5-1 plan) | −34,000 | $98.47 | $3.35M | 280,209 |
| Ugur Sahin Chief Executive Officer, 10% owner | Sep 25, 2026 | Sale(10b5-1 plan) | −27,000 | $98.69 | $2.66M | 314,209 |
| Ugur Sahin Chief Executive Officer, 10% owner | Sep 24, 2026 | Sale(10b5-1 plan) | −39,000 | $98.99 | $3.86M | 341,209 |
| Ugur Sahin Chief Executive Officer, 10% owner | Sep 23, 2026 | Sale(10b5-1 plan) | −30,000 | $99.40 | $2.98M | 380,209 |
| Ugur Sahin Chief Executive Officer, 10% owner | Sep 22, 2026 | Sale(10b5-1 plan) | −46,000 | $100.72 | $4.63M | 410,209 |
| Ugur Sahin Chief Executive Officer, 10% owner | Sep 21, 2026 | Sale(10b5-1 plan) | −33,000 | $97.81 | $3.23M | 456,209 |
| Ugur Sahin Chief Executive Officer, 10% owner | Sep 18, 2026 | Sale(10b5-1 plan) | −30,000 | $96.22 | $2.89M | 489,209 |
| Ugur Sahin Chief Executive Officer, 10% owner | Sep 17, 2026 | Sale(10b5-1 plan) | −34,000 | $98.60 | $3.35M | 519,209 |
| Ugur Sahin Chief Executive Officer, 10% owner | Sep 16, 2026 | Sale(10b5-1 plan) | −15,000 | $96.09 | $1.44M | 553,209 |
| Ugur Sahin Chief Executive Officer, 10% owner | Sep 15, 2026 | Sale(10b5-1 plan) | −34,000 | $96.49 | $3.28M | 568,209 |
| Ugur Sahin Chief Executive Officer, 10% owner | Sep 14, 2026 | Sale(10b5-1 plan) | −41,000 | $99.45 | $4.08M | 602,209 |
| Ugur Sahin Chief Executive Officer, 10% owner | Sep 11, 2026 | Sale(10b5-1 plan) | −45,000 | $96.93 | $4.36M | 643,209 |
| Ugur Sahin Chief Executive Officer, 10% owner | Sep 10, 2026 | Sale(10b5-1 plan) | −20,500 | $96.31 | $1.97M | 688,209 |
| Ugur Sahin Chief Executive Officer, 10% owner | Sep 9, 2026 | Sale(10b5-1 plan) | −36,000 | $97.78 | $3.52M | 708,709 |
| Ugur Sahin Chief Executive Officer, 10% owner | Sep 8, 2026 | Sale(10b5-1 plan) | −37,000 | $99.20 | $3.67M | 744,709 |
| Ugur Sahin Chief Executive Officer, 10% owner | Sep 4, 2026 | Sale(10b5-1 plan) | −31,500 | $103.52 | $3.26M | 781,709 |
| Ugur Sahin Chief Executive Officer, 10% owner | Sep 3, 2026 | Sale(10b5-1 plan) | −45,000 | $102.85 | $4.63M | 813,209 |
| Sierk Poetting Chief Operating Officer | Apr 22, 2026 | Sale(10b5-1 plan) | −50,000 | $110.56 | $5.53M | 399,387 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of BioNTech's stock actually held short. Settlement fails (shares not delivered on time) peaked at 233,023 shares on Aug 20, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Medine GmbH Officer, 10% Stockholder | Sep 3, 2026 | 858,209 | $89.09M | Sep 3, 2026 | Stock Option Exercise |
| Medine GmbH Officer, 10% Stockholder | May 12, 2026 | 858,209 | $80.38M | May 13, 2026 | Stock Option Exercise |
| Sierk Poetting Officer | Mar 11, 2026 | 150,000 | $12.58M | Mar 11, 2026 | Stock Option Exercise |
| Medine GmbH Officer, 10% Stockholder | Feb 12, 2026 | 858,209 | $93.87M | Feb 12, 2026 | Stock Option Exercise |
| Ozlem Tureci Officer | Nov 28, 2025 | 123,331 | $12.67M | Nov 28, 2025 | Stock Option Exercise |
| Medine GmbH Officer, 10% Stockholder | Nov 13, 2025 | 1,114,130 | $124.45M | Nov 13, 2025 | Stock Option Exercise |
| Helmut Wolfgang Jeggle Director | Nov 5, 2025 | 150,000 | $15.51M | Nov 5, 2025 | Private placement |
| Athos Kg 10% Stockholder | Sep 5, 2025 | 500,000 | $56.23M | Sep 5, 2025 | Private placement |
| Ozlem Tureci Officer | Aug 15, 2025 | 185,001 | $20.85M | Aug 15, 2025 | Stock Option Exercise |
| Medine GmbH Officer, 10% Stockholder | Aug 15, 2025 | 1,774,837 | $200.02M | Aug 15, 2025 | Stock Option Exercise |
| Athos Kg 10% Stockholder | Jun 4, 2025 | 325,000 | $36.76M | May 28, 2025 | Private placement |
| Helmut Wolfgang Jeggle Director | Jun 4, 2025 | 150,000 | $16.97M | Jun 4, 2025 | Private placement |
| Athos Kg 10% Stockholder | Jun 2, 2025 | 175,000 | $19.39M | Jun 2, 2025 | Private placement |
| Athos Kg 10% Stockholder | May 28, 2025 | 500,000 | $49.34M | May 28, 2025 | Private placement |
| Helmut Wolfgang Jeggle Director | May 7, 2025 | 150,000 | $14.21M | May 7, 2025 | Private placement |
See a number that looks wrong?